【摘要】：目的評(píng)價(jià)替加環(huán)素治療重癥患者呼吸機(jī)相關(guān)性肺炎(VAP)的臨床療效與安全性。方法選取2011年1月1日至2013年5月31日山東大學(xué)齊魯醫(yī)院重癥監(jiān)護(hù)病房的VAP患者33例,給予替加環(huán)素治療,初始劑量100 mg,維持劑量50 mg,靜脈滴注,每隔12 h注射1次,根據(jù)患者具體病情確定給藥療程。評(píng)價(jià)患者的臨床成功率、細(xì)菌清除率及安全性。結(jié)果入組病例37例,最終可評(píng)價(jià)病例33例,臨床成功率61%(20/33)。共分離得到36株多重耐藥菌,均對(duì)替加環(huán)素敏感,總清除率61%(22/36),其中分離率最高的鮑曼不動(dòng)桿菌清除率60%(18/30)。不良反應(yīng)以消化道癥狀為主,經(jīng)臨床對(duì)癥治療后好轉(zhuǎn)。6例于治療28 d內(nèi)死亡。結(jié)論替加環(huán)素治療危重患者VAP療效確切,耐受性良好。
[Abstract]:Objective to evaluate the efficacy and safety of tegacycline in the treatment of severe ventilator-associated pneumonia (VAP). Methods from January 1, 2011 to May 31, 2013, 33 VAP patients in the intensive care unit of Qilu Hospital of Shandong University were treated with tegacycline. The initial dose was 100 mg, maintenance dose 50 mg, intravenous drip, once every 12 hours. The course of treatment was determined according to the patient's specific condition. To evaluate the clinical success rate, bacterial clearance rate and safety of the patients. Results 37 cases were enrolled and 33 cases were finally evaluated. The clinical success rate was 61% (20 / 33). A total of 36 strains of multidrug-resistant bacteria were isolated, all of which were sensitive to tegacycline. The total clearance rate was 61% (22 / 36), and that of Acinetobacter baumannii with the highest isolation rate was 60% (18 / 30). The adverse reactions were mainly alimentary tract symptoms and improved after clinical symptomatic treatment. 6 cases died within 28 days of treatment. Conclusion Tegacycline is effective and tolerable in the treatment of VAP in critically ill patients.
【作者單位】： 山東大學(xué)齊魯醫(yī)院重癥醫(yī)學(xué)科;山東大學(xué)齊魯醫(yī)院感染管理處;
【基金】：衛(wèi)生部國(guó)家臨床重點(diǎn)專(zhuān)科建設(shè)項(xiàng)目(2011-873) 中華醫(yī)學(xué)會(huì)臨床醫(yī)學(xué)科研專(zhuān)項(xiàng)(1103016060)
【分類(lèi)號(hào)】：R563.1

【相似文獻(xiàn)】

相關(guān)期刊論文 前3條

1 王艷紅;吳本權(quán);羅進(jìn)梅;黃靜;;替加環(huán)素聯(lián)合頭孢哌酮-舒巴坦治療醫(yī)院獲得性泛耐藥鮑氏不動(dòng)桿菌肺炎10例[J];中國(guó)新藥與臨床雜志;2014年03期

2 張杰根;戴富林;韓碩;王剛;;替加環(huán)素聯(lián)合舒巴坦治療泛耐藥鮑氏不動(dòng)桿菌肺部感染的臨床療效觀察[J];中華醫(yī)院感染學(xué)雜志;2014年01期

3 ;[J];;年期

相關(guān)會(huì)議論文 前1條

1 阮肇?fù)P;呂群;馬潛;戴一帆;馮哲敏;;替加環(huán)素治療碳青霉烯耐藥肺炎克雷伯菌呼吸機(jī)相關(guān)性肺炎2例體會(huì)[A];華東地區(qū)第13屆中青年呼吸論壇論文集[C];2012年

相關(guān)碩士學(xué)位論文 前1條

1 屈慶會(huì);替加環(huán)素與舒巴坦聯(lián)合應(yīng)用對(duì)泛耐藥鮑曼不動(dòng)桿菌體外抗菌活性的研究[D];泰山醫(yī)學(xué)院;2013年

，

本文編號(hào)：2448174